TANGO Therapeutics will employ two CRISPR technologies invented by Ulrich Elling at IMBA and in part by Krzysztof Chylinski at VBCF to discover genes involved in tumourigenesis and immune evasion as targets for next-generation therapies.
The method, SARSeq (Saliva Analysis by RNA sequencing), enables highly sensitive, massively-parallel and cost-effective testing for SARS-CoV-2. Ascenion has supported its patent protection and licencing for commercial use in China.
Heidelberg Pharma AG is allowed to initiate a Phase I/IIa clinical study in the US to evaluate the dosing, safety and anti-tumour efficacy of its lead candidate HDP-101 in multiple myeloma.
Diffratec, a spin-off from the Medical University of Innsbruck (MUI), commercializes breakthrough diffractive elements. These elements, in particular Moiré lenses, are extremely compact and tunable with high speed and precision.
Ascenion GmbH, technology transfer partner of the Max Delbrück Center for Molecular Medicine (MDC), has supported the conclusion of an agreement between the MDC and Fate Therapeutics, Inc.
Agreement with Max Delbrück Center Provides Access to Broad Intellectual Property Portfolio of Unique Humanized Antibody Fragments and Antigen-Binding…
BigChem GmbH was founded this October to commercialize validated IT products and services developed at the Helmholtz Zentrum München. The research was…